PITTSBURGH, Jan. 2, 2014 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that Rakesh Bamzai has joined the company and has been appointed president, India Commercial and Emerging Markets. Bamzai has more than 20 years of experience in the Indian and global biopharmaceutical industry. Prior to joining Mylan, he was president of Marketing at Biocon, […]
PITTSBURGH, Dec. 18, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist (LAMA) compound for various indications. Mylan expects that this product, which is ready to […]
Agreement includes a no-later-than July 9, 2015 launch PITTSBURGH, Dec. 17, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will […]
PITTSBURGH, Dec. 5, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Cabergoline Tablets USP, 0.5 mg. Cabergoline Tablets USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan received final approval from the U.S. Food and Drug Administration […]
Purchase Price Restructured to Hold Back $250 Million Contingent Upon Satisfaction of Certain Regulatory Conditions Mylan Board of Directors Sets April 11, 2014 as Date for Annual Meeting of Shareholders PITTSBURGH, Dec. 4, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that it has completed the acquisition of the Agila injectables businesses from Strides […]
PITTSBURGH, Dec. 1, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL), one of the world’s leading pharmaceutical companies, and the Elton John AIDS Foundation (EJAF) today announced that they will give a combined $1 million to the Business Leadership Council for a Generation Born HIV Free (BLC) for the elimination of mother-to-child transmission (eMTCT) of HIV […]
PITTSBURGH, Nov. 25, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India. This is the first regulatory approval for a Mylan-Biocon developed biosimilar product. The product is a biosimilar to Roche’s Herceptin®, indicated for the treatment […]
– Company awarded 180 days marketing exclusivity – PITTSBURGH, Nov. 18, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Dexmethylphenidate Hydrochloride Extended-release (ER) Capsules, 30 mg, which is the first generic version of Novartis’ Focalin XR®. Mylan was the first company to have filed a substantially […]